Successful Treatment of Refractory Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Syndrome and Paradoxical Psoriasis with Secukinumab: A Case Report
Authors:
Open Access
- 1 March 2024
- journal article
- case report
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 17, 547-552
Abstract
Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is a rare chronic inflammatory disease mainly manifested as skin and osteoarticular lesions. Herein, we describe a female patient with SAPHO syndrome exhibited paradoxical psoriasis and primary palmoplantar pustulosis (PPP) worsened during treatment with adalimumab. We then switched to secukinumab and obtained significant improvement in both skin lesions and osteoarticular pain. These findings suggest that secukinumab might be an appropriate option for patients with SAPHO syndrome who present with TNF-α-inhibitor-induced paradoxical psoriasis.Keywords
This publication has 19 references indexed in Scilit:
- SAPHO syndrome: current clinical, diagnostic and treatment approachesRheumatology International, 2023
- Whole-Exome Sequencing in 10 Unrelated Patients with Syndromic Hidradenitis Suppurativa: A Preliminary Step for a Genotype-Phenotype CorrelationDermatology, 2022
- Similarity and difference between palmoplantar pustulosis and pustular psoriasisThe Journal of Dermatology, 2021
- Successful treatment of refractory mandibular lesions in SAPHO syndrome with secukinumabRheumatology, 2020
- Histologic comparison of tumor necrosis factor-α inhibitor–induced psoriasis and psoriasis vulgarisJournal of the American Academy of Dermatology, 2020
- Synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: review and updateTherapeutic Advances in Musculoskeletal Disease, 2020
- Successful treatment of co‐existent SAPHO syndrome and hidradenitis suppurativa with adalimumab and methotrexateJournal of the European Academy of Dermatology and Venereology, 2019
- Biologics in SAPHO syndrome: A systematic reviewSeminars in Arthritis and Rheumatism, 2019
- Paradoxical skin lesions induced by anti-TNF-α agents in SAPHO syndromeClinical Rheumatology, 2018
- Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatmentGut, 2013